INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 12 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $11,232,000 | 0.0% | 18,590,000 | 0.0% | 0.14% | -12.7% |
| Q4 2021 | $11,232,000 | -8.9% | 18,590,000 | -9.7% | 0.16% | -6.2% |
| Q3 2021 | $12,327,000 | -25.6% | 20,590,000 | -17.6% | 0.18% | +36.4% |
| Q2 2021 | $16,578,000 | – | 25,000,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 11,795,000 | $10,081,000 | 2.79% |
| Context Capital Management, LLC | 9,795 | $6,281,000 | 0.45% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $144,000 | 0.02% |
| Calamos Advisors LLC | 5,000,000 | $3,209,000 | 0.01% |
| FRANKLIN RESOURCES INC | 21,000,000 | $13,885,000 | 0.01% |
| FMR LLC | 17,435,000 | $11,397,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| MORGAN STANLEY | 1,601,000 | $1,036,000 | 0.00% |